BioSpace News Archive

Choose your raw materials wisely

AbbVie and Johnson & Johnson will withdraw the accelerated approvals for Imbruvica in mantle cell lymphoma and marginal zone lymphoma, the companies announced Thursday.

The Boston Business Journal reported the layoffs would affect the multiple sclerosis team, but Biogen declined to confirm the details.

Gritstone bio, Inc. today announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 20,000 shares of its common stock with an exercise price of $2.76, which is equal to the closing price of Gritstone’s common stock on April 3, 2023.

Miromatrix Medical Inc. announced that CEO Jeff Ross, Ph.D will present at the 2023 Cell & Gene Meeting on the Mediterranean.

Virginia Commonwealth University’s Stravitz-Sanyal Institute for Liver Disease and Metabolic Health has announced a partnership with Singapore -headquartered medtech company, Histoindex Pte Ltd.

ProMIS Neurosciences Inc. today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for PMN310 for the treatment of AD.

JW Therapeutics announced that it has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for a clinical trial of relmacabtagene autoleucel injection (relma-cel) in patients with moderately or severely refractory systemic lupus erythematosus (SLE).

Ovid Therapeutics Inc. today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023 at 11:00 a.m. ET.

MBX Biosciences, Inc. today announced its participation at the virtual Needham 22nd Annual Healthcare Conference. Kent Hawryluk, President and Chief Executive Officer, will present on Monday, April 17, 2023 at 3:00 p.m. ET.